WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising


micronized Compound A, and/or

micronized at least one pharmaceutically acceptable salt of Compound A, and

at least one pharmaceutically acceptable excipient,

wherein the micronized Compound A and/or the micronized at least one pharmaceutically acceptable salt of Compound A has a particle size distribution (PSD) D90 value ranging from greater than 2.0 to 12.0 µm,


wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



.

2. A pharmaceutical composition, comprising at least one pharmaceutically acceptable excipient and micronized Compound A having a particle size distribution (PSD) D90 value ranging from greater than 2.0 to 12.0 µm,

wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



.

3. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

4. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized substantially pure Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

5. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized Form II *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

6. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized substantially pure Form II N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.


7. The pharmaceutical composition of any one of claims 1-6, wherein the D90 value ranges from greater than 2.0 to 11.0 µm.

8. The pharmaceutical composition of any one of claims 1-6, wherein the D90 value is between 3.0 and 4.0 µm.

9. The pharmaceutical composition of any one of claims 1-8, wherein the at least one pharmaceutically acceptable excipient is chosen from diluents, disintegrants, granulation binders, and glidants.

10. The pharmaceutical composition of claim 9, wherein the diluent is selected from mannitol, microcrystalline cellulose, starch, lactose, dextrin and sorbitol; the disintegrant is sodium starch glycolate; the granulation binder is polyvinylpyrrolidone; and/or the glidant is selected from silicon dioxide and magnesium stearate.

11. A compound comprising micronized Compound A, and/or a micronized pharmaceutically acceptable salt of Compound A;
wherein the micronized Compound A and/or the micronized pharmaceutically acceptable salt of Compound A has a particle size distribution (PSD) D90 value ranging from greater than 2.0 to 12.0 µm; and wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



12. The compound of claim 11, wherein the micronized Compound A is micronized Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

13. The compound of claim 11, wherein the micronized Compound A is micronized substantially pure Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

14. The compound of claim 11, wherein the micronized Compound A is micronized Form II *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

15. The compound of claim 11, wherein the micronized Compound A is micronized substantially pure Form II N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

16. The compound of claim 11, wherein the D90 value ranges from greater than 2.0 and 11.0 µm.

17. The compound of claim 11, wherein the D90 value is between 3.0 and 4.0 µm.

18. The pharmaceutical composition according to any one of claims 1-10, or the compound according to any one of claims 11-17, for use in treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition; wherein said disease is an angiogenesis-related disease selected from cancer and age-related macular degeneration, and said cancer is selected from lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, stomach cancer, kidney cancer, liver cancer, brain cancer, bone cancer, thyroid cancer, neuroendocrine tumors, sarcoma, and leukemia.

19. Use of the pharmaceutical composition according to any one of claims 1-10 or the compound according to any one of claims 11-17 in the manufacture of a medicament for treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition; wherein said disease is an angiogenesis-related disease selected from cancer and age-related macular degeneration, and said cancer is selected from lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, stomach cancer, kidney cancer, liver cancer, brain cancer, bone cancer, thyroid cancer, neuroendocrine tumors, sarcoma, and leukemia.